Skip to main content
. 2022 Nov 16;17(11):e0277566. doi: 10.1371/journal.pone.0277566

Fig 1. Decision tree structure (ABA-1L vs. TNFi-1L).

Fig 1

The target population was RA patients who had an inadequate response to prior treatment with at least one csDMARD, including MTX, in clinical practice. The cost-effectiveness was compared between ABA SC-1L ± MTX and TNFi-1L ± MTX. 1L, first line; ABA, abatacept; csDMARD, conventional synthetic disease-modifying antirheumatic drug; JPY, Japanese Yen; MTX, methotrexate; RA, rheumatoid arthritis; SC, subcutaneous; TNFi, tumour necrosis factor inhibitor.